- Conditions
- Rehabilitation, ACL Reconstruction
- Interventions
- HOME, TNMT
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 13 Years to 30 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Flowery Branch, Georgia • Minneapolis, Minnesota • Rochester, Minnesota + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 545
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hormone-sensitive Metastatic Breast Cancer
- Interventions
- OSI-906, Erlotinib, Letrozole, Goserelin
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Franklin, Tennessee • Nashville, Tennessee
- Conditions
- Gait, Balance, Biomechanical Data, Postural Control, Locomotion
- Interventions
- Sensor-enabled Athletic X Ankle Brace (sXAB)
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 30
- States / cities
- Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
- Conditions
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Interventions
- Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Marizomib, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- TAK-228, Letrozole
- Drug
- Lead sponsor
- Gary Schwartz
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Essential Hypertension
- Interventions
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg, Aprocitentan 50 mg, Lisinopril 20 mg, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 74
- States / cities
- Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Interventions
- Carfilzomib, Irinotecan
- Drug
- Lead sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 8
- States / cities
- Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
- Conditions
- Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma
- Interventions
- PEGPH20, CIS, GEM, Atezolizumab
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Bevacizumab, Lenalidomide, Docetaxel, Prednisone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- High-risk Diffuse Large B-Cell Lymphoma
- Interventions
- Blinatumomab, Investigator's Choice Chemotherapy, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Maywood, Illinois • New Orleans, Louisiana + 5 more
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Fresno, California • Fullerton, California + 16 more
- Conditions
- Uncontrolled Gout
- Interventions
- Pegloticase, Methotrexate (MTX)
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 12 more
- Conditions
- Gastroparesis, Diabetes Mellitus
- Interventions
- Placebo, Relamorelin
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 183
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 144 more
- Conditions
- Hypertension
- Interventions
- LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Control-IQ technology 2.0
- Device
- Lead sponsor
- Tandem Diabetes Care, Inc.
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Brexpiprazole, Sertraline, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Etokimab, Placebo, Mometasone Furoate Nasal Spray
- Biological · Drug
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Canoga Park, California • Roseville, California + 24 more
- Conditions
- Primary Immunodeficiency
- Interventions
- Gamunex-C, IVIG-PEG
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more
- Conditions
- Lymphoma
- Interventions
- Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Miami, Florida • Stony Brook, New York + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more